{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:34:51Z","timestamp":1789893291857,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1111\/bjd.14601","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T08:39:03Z","timestamp":1459413543000},"page":"296-301","source":"Crossref","is-referenced-by-count":160,"title":["Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database"],"prefix":"10.1093","volume":"175","author":[{"given":"J.","family":"B\u00e9n\u00e9","sequence":"first","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance du Nord Pas-de-Calais; Univ.Lille; CHU Lille; F-59000 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moulis","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne; CHU de Toulouse; Toulouse France"},{"name":"UMR 1027 INSERM-Universit\u00e9 Paul Sabatier; Toulouse France"},{"name":"Centre d'Investigation Clinique 1436; CHU de Toulouse; France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bennani","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; CHU de Toulouse; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Auffret","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance du Nord Pas-de-Calais; Univ.Lille; CHU Lille; F-59000 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Coupe","sequence":"additional","affiliation":[{"name":"Service Pharmacie; Centre Hospitalier de Valenciennes; Valenciennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Babai","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de PharmacoVigilance; H\u00f4pital Henri Mondor; Assistance Publique H\u00f4pitaux de Paris; Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hillaire-Buys","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de PharmacoVigilance; D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie; Facult\u00e9 de M\u00e9decine et CHRU; Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Micallef","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de PharmacoVigilance; Service de Pharmacologie Clinique et Pharmacovigilance; Assistance Publique des H\u00f4pitaux de Marseille; Aix Marseille Universit\u00e9; Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gautier","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance du Nord Pas-de-Calais; Univ.Lille; CHU Lille; F-59000 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the French Association of Regional PharmacoVigilance Centres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"10.1111\/bjd.14601-BIB0001|bjd14601-cit-0001","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1111\/bjd.14601-BIB0002|bjd14601-cit-0002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/bjd.14601-BIB0003|bjd14601-cit-0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1111\/bjd.14601-BIB0004|bjd14601-cit-0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14656566.2012.642866","article-title":"A review of gliptins in 2011","volume":"13","author":"Scheen","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/bjd.14601-BIB0005|bjd14601-cit-0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archinternmed.2010.188","article-title":"Sitagliptin-associated drug allergy: review of spontaneous adverse event reports","volume":"170","author":"Desai","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1111\/bjd.14601-BIB0006|bjd14601-cit-0006","first-page":"123","article-title":"Sitagliptin: serious allergies. Risks greater than benefits","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"10.1111\/bjd.14601-BIB0007|bjd14601-cit-0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.diabet.2012.07.002","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin","volume":"38","author":"Sin","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1111\/bjd.14601-BIB0008|bjd14601-cit-0008","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2010.02973.x","article-title":"Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report","volume":"27","author":"Skalli","year":"2010","journal-title":"Diabet Med"},{"key":"10.1111\/bjd.14601-BIB0009|bjd14601-cit-0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.14601-BIB0010|bjd14601-cit-0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J Dermatol Case Rep"},{"key":"10.1111\/bjd.14601-BIB0011|bjd14601-cit-0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases","volume":"29","author":"B\u00e9n\u00e9","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/bjd.14601-BIB0012|bjd14601-cit-0012","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1111\/bjd.14601-BIB0013|bjd14601-cit-0013","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14601-BIB0014|bjd14601-cit-0014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.14601-BIB0015|bjd14601-cit-0015","first-page":"557","article-title":"[French pharmacovigilance database system: examples of utilization]","volume":"50","author":"Moore","year":"1995","journal-title":"Th\u00e9rapie"},{"key":"10.1111\/bjd.14601-BIB0016|bjd14601-cit-0016","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","article-title":"[Pharmacovigilance in practice]","volume":"6","author":"Spreux","year":"1999","journal-title":"Transfus Clin Biol"},{"key":"10.1111\/bjd.14601-BIB0017|bjd14601-cit-0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1111\/bjd.14601-BIB0018|bjd14601-cit-0018","first-page":"111","article-title":"[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Th\u00e9rapie"},{"key":"10.1111\/bjd.14601-BIB0019|bjd14601-cit-0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2515\/therapie\/2015028","article-title":"Validation and reproducibility of the updated French causality assessment method: an evaluation by pharmacovigilance centres & pharmaceutical companies","volume":"70","author":"Th\u00e9ophile","year":"2015","journal-title":"Th\u00e9rapie"},{"key":"10.1111\/bjd.14601-BIB0020|bjd14601-cit-0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.14601-BIB0021|bjd14601-cit-0021","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":"Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database","volume":"44","author":"Moore","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/bjd.14601-BIB0022|bjd14601-cit-0022","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/bjd.14601-BIB0023|bjd14601-cit-0023","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.14601-BIB0024|bjd14601-cit-0024","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1111\/bjd.14601-BIB0025|bjd14601-cit-0025","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.14601-BIB0026|bjd14601-cit-0026","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14601-BIB0027|bjd14601-cit-0027","volume-title":"Launch Excellence in the Diabetes Market","author":"IMS Health","year":"2012"},{"key":"10.1111\/bjd.14601-BIB0028|bjd14601-cit-0028","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0192623313516828","article-title":"Vascular origin of vildagliptin-induced skin effects in cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y","volume":"42","author":"Hoffmann","year":"2014","journal-title":"Toxicol Pathol"},{"key":"10.1111\/bjd.14601-BIB0029|bjd14601-cit-0029","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin","volume":"134","author":"List","year":"2006","journal-title":"Regul Pept"},{"key":"10.1111\/bjd.14601-BIB0030|bjd14601-cit-0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200932070-00005","article-title":"Statins and erectile dysfunction: results of a case\/non-case study using the French Pharmacovigilance System Database","volume":"32","author":"Do","year":"2009","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.14601-BIB0031|bjd14601-cit-0031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/0002018-200831120-00007","article-title":"Statin-associated psychiatric adverse events: a case\/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting","volume":"31","author":"Tuccori","year":"2008","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.14601-BIB0032|bjd14601-cit-0032","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/11595660-000000000-00000","article-title":"Serotonin reuptake inhibitors and hyperprolactinaemia: a case\/non-case study in the French pharmacovigilance database","volume":"34","author":"Trenque","year":"2011","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.14601-BIB0033|bjd14601-cit-0033","first-page":"562","article-title":"Furosemide-induced bullous pemphigoid: case report and review of literature","volume":"5","author":"Lee","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.14601-BIB0034|bjd14601-cit-0034","first-page":"1","volume-title":"Advances in Inflammatory Research","author":"Weber","year":"1984"},{"key":"10.1111\/bjd.14601-BIB0035|bjd14601-cit-0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2125.1997.t01-1-00573.x","article-title":"Temporal trends in spontaneous reporting of unlabelled adverse drug reactions","volume":"44","author":"Haramburu","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/bjd.14601-BIB0036|bjd14601-cit-0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","article-title":"Trends of reporting of \u2018serious\u2019 vs. \u2018non-serious\u2019 adverse drug reactions over time: a study in the French PharmacoVigilance Database","volume":"74","author":"Moulis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/bjd.14601-BIB0037|bjd14601-cit-0037","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/bjd.14601-BIB0038|bjd14601-cit-0038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","article-title":"Is reporting rate a good predictor of risks associated with drugs?","volume":"47","author":"Pierfitte","year":"1999","journal-title":"Br J Clin Pharmacol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14601","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.14601\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:20:10Z","timestamp":1676366410000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/175\/2\/296\/6616634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14601","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726256239.793522680","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726256239.793549771","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}